Diaceutics PLC Diaceutics PLC - Planned CEO Transition (5960N)
26 Settembre 2023 - 8:00AM
UK Regulatory
TIDMDXRX
RNS Number : 5960N
Diaceutics PLC
26 September 2023
Diaceutics PLC - Planned CEO Transition
Peter Keeling stepping back as CEO, Ryan Keeling appointed CEO
Designate
Belfast and London, 26 September 2023 - Diaceutics PLC (AIM:
DXRX) , a leading technology and solutions provider to the
pharmaceutical industry, today announces details of its planned CEO
transition.
Having co-founded the Company and spent 18 years as its CEO,
Peter Keeling has informed the Board of his intention to step back
as CEO of Diaceutics on 1 January 2024. He will continue to serve
on the Board as an Executive Director, to support the CEO
transition. Thereafter, Peter's primary focus will be to accelerate
the corporate development of Diaceutics. This will further
strengthen Diaceutics leadership position as the primary partner
for pharmaceutical companies as they seek to commercialise the new
generation of precision therapeutics across a range of disease
areas over the coming months and years.
Peter Keeling co-founded Diaceutics in 2005 and has led the
growth of the Company from a niche consulting service provider to a
high margin, high growth diagnostic commercialisation platform. The
Company now serves 21 of the top 30 global pharma companies, with
161 people across Europe and North America and a network of 900
laboratories worldwide. Peter also led the Company's public listing
in 2019.
Ryan Keeling, current Chief Innovation Officer, has today been
appointed CEO Designate and will become CEO on 1 January 2024. Ryan
joined Diaceutics in 2006 and became a member of the Board on IPO
in 2019. His current responsibilities as Chief Innovation Officer
will be split between the Chief Commercial Officer and Chief Data
Officer during the transition period.
Ryan is an expert in the commercialisation of diagnostics and
associated technology, with over 17 years' experience in the field.
He is the architect of the Company's data capabilities and DXRX
platform, leading the development and commercialisation of the
Group's technology, including its proprietary data lake . During
his tenure with Diaceutics, Ryan has underpinned the Company's
growth, holding the key roles of Chief Commercial Officer, Chief
Operating Officer and most recently, Chief Innovation Officer where
he has led the Group's product innovation, with a near term focus
on the development of DXRX.
Deborah Davis, Chair of Diaceutics, commented: "Peter has been
instrumental in making Diaceutics what it is today. Since
co-founding the business 18 years ago, Peter has led the evolution
of our Company including our IPO in 2019. For nearly two decades,
he has been a central force behind Diaceutics' performance and
growth and it is reassuring that we will retain the benefit of his
wisdom and industry thought leadership at Board level in the
future. Ryan has been a core part of our growth and development
since he joined the Company in 2006 and is an exceptionally capable
leader. I look forward to continuing to work with him as we realise
the full scale of the market opportunity, helping our pharma
customers identify patients in need of therapy."
Peter Keeling, CEO of Diaceutics, commented: "After 18 years
building and shaping the business as CEO, I believe Diaceutics has
established an important position with our customers as a thought
leader in the global precision medicine market. My decision to hand
over at this time is made easy knowing how well the Company is now
positioned for growth with the talent and motivation of the
exceptional team in the business today. Having worked closely with
Ryan for more than 17 years, I have complete confidence in him to
lead Diaceutics successfully into the future, and I look forward to
supporting him and the wider team. It has been my great privilege
to work alongside so many leaders from pharmaceutical and
laboratory companies, as we built a business which is increasing
the treatment opportunities for patients every single day. I would
like to take this opportunity to thank everyone at Diaceutics for
creating the important business that we are today; and for the
support they have provided to me personally throughout these
foundational years in Diaceutics."
Ryan Keeling, CEO Designate, commented: "Diaceutics is a
thriving, growing and global business. I am excited to be taking on
the role of CEO and look forward to building on the success that
has been created over nearly two decades.
I would like to thank Peter for his leadership and support and
the Board for the confidence they have placed in me to lead our
exceptional business into the future. I am fortunate to be
surrounded by a remarkable and talented team and look forward to
executing against the ambitious plans we have for the
business."
The Company will today announce its interim results for the six
months to 30 June 2023.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 as it forms part of UK
domestic law by virtue of the European Union (Withdrawal) Act 2018
("MAR"), and is disclosed in accordance with the Company's
obligations under Article 17 of MAR. The person responsible for
making this announcement on behalf of the Company is Nick Roberts,
Chief Financial Officer.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Tel: +44 (0)28 9040
6500
Ryan Keeling, Chief Executive Officer investorrelations@diaceutics.com
Designate
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with
an end-to-end commercialisation solution for precision medicines
through data analytics, scientific and advisory services enabled by
our platform DXRX - The Diagnostics Network (R)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASESESIEDSEFU
(END) Dow Jones Newswires
September 26, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Mag 2023 a Mag 2024